MAP2K7 and breast cancer: On the other hand, the EGFR pathway is known to mediate BCSCs.[59, 60] In clinical samples and patient‐derived xenografted models (PDXs), EGFR is highly correlated with stemness of breast cancer.[61, 62] Furthermore, EGFR inhibitors are reported to be responsible for elimination of BCSCs.[3] For downstream signaling, EGFR modulates BCSCs through both the PI3K‐AKT and MEK/ERK pathways in TNBC.[63, 64] Besides PI3K‐AKT signaling (Figure 4), our data indicated that ERK phosphorylation decreased upon SGCE knockdown (Figure S8B, Supporting Information), further supporting the above reports.